Pfizer

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for underserved patient communities, particularly those affected by blood disorders. The company is advancing its lead product candidate, Oxbryta (voxelotor), which is an oral, once-daily therapy designed for the treatment of sickle cell disease (SCD). Oxbryta has completed Phase III clinical trials in adult and adolescent patients and is currently being evaluated for safety and pharmacokinetics in a Phase IIa trial involving pediatric patients. In addition to its efforts in SCD, Global Blood Therapeutics is engaged in research and development for other blood-related conditions, including hereditary angioedema, and holds licensed rights to its product candidates in multiple regions, including the United States and Europe.

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for neurological diseases and other therapeutic areas. The company focuses on life-changing therapies targeting conditions such as neuromuscular disorders, metabolic diseases, obsessive-compulsive disorder, and various forms of cancer. Its diverse pipeline includes late-stage product candidates that utilize mechanisms such as calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Notable candidates in its pipeline include BHV3000-301, BHV3000-302, and BHV3000-303, among others. Biohaven's commitment to addressing unmet medical needs positions it as a significant player in the biopharmaceutical landscape.

ResApp Health Limited is a developer of digital healthcare solutions focused on enabling doctors and patients to diagnose and manage respiratory diseases. Founded in 2014 and headquartered in Brisbane, Australia, the company offers ResAppDx, a smartphone-based diagnostic test for acute respiratory diseases, suitable for telehealth, emergency departments, and primary care settings. Additionally, it provides SleepCheck, a direct-to-consumer application for self-assessing sleep apnoea in multiple countries. ResApp's technology leverages sound analysis to identify various respiratory conditions, including pneumonia, bronchiolitis, and asthma. The company is committed to creating user-friendly, clinically validated, and regulatory-approved diagnostic tools that integrate seamlessly into existing telehealth frameworks, enhancing accessibility for both healthcare providers and patients. ResApp Health was previously known as Narhex Life Sciences Limited.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing innovative medicines for various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. Founded in 1997, the company focuses on pharmacology and pharmacokinetics, advancing several investigational drugs through clinical trials. Notable candidates include Etrasimod, which is in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn’s disease, and Olorinab, currently in Phase IIb trials for abdominal pain linked to irritable bowel syndrome. Additionally, Arena is developing ralinepag for pulmonary arterial hypertension and APD418 for acute heart failure. The company has formed collaborations with several organizations, including United Therapeutics and Eisai, to enhance its research and expand its market presence. Arena Pharmaceuticals also has a marketed product, lorcaserin, approved for weight management, further demonstrating its commitment to addressing critical health challenges through innovative therapies.

Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company based in Mississauga, Canada, that specializes in developing therapies for cancer treatment. The company focuses on harnessing the immune system to combat malignancies through innovative protein therapeutics. Its lead program, TTI-621, is a SIRPaFc fusion protein currently undergoing Phase I clinical trials for advanced relapsed or refractory hematologic malignancies, solid tumors, and mycosis fungoides. Additionally, Trillium is advancing TTI-622, another SIRPaFc protein in Phase I trials, while also exploring TTI-10001, a small molecule stimulator of interferon genes agonist in the discovery phase. Originally founded in 2004, the company has undergone several name changes, reflecting its evolving focus within the biopharmaceutical sector.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Arixa Pharmaceuticals, Inc. is a biotechnology company focused on developing oral antibiotics to combat drug-resistant Gram-negative infections. Founded in 2016 and based in Palo Alto, California, the company is advancing its lead product, ARX-1796, an oral prodrug of Avibactam, a broad-spectrum beta-lactamase inhibitor approved by the FDA. Arixa utilizes a unique prodrug chemistry technology platform that transforms intravenous-only antimicrobial agents into formulations suitable for oral administration. This innovation addresses significant medicinal chemistry challenges associated with prodrug development in this class of compounds. Arixa aims to provide effective treatment options for patients suffering from bacterial infections, while also securing broad patent protection for its proprietary formulations.

Array BioPharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other significant diseases. Founded in 1998 and headquartered in Boulder, Colorado, the company focuses on clinical-stage drugs, including binimetinib, encorafenib, selumetinib, tucatinib, and several others. Array BioPharma has established partnerships with major pharmaceutical companies, such as AstraZeneca and Roche, to enhance its drug development and commercial capabilities. The company operates across North America, Europe, and the Asia Pacific, underscoring its commitment to providing innovative therapies for patients in need.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

IGNITE Immunotherapy is focused on advancing cancer treatment through innovative immunotherapy solutions. The company specializes in the development of optimized intravenous oncolytic virus vaccines, which are designed to enhance the effectiveness of existing immune checkpoint inhibitors. By igniting a targeted immune response against cancer, IGNITE aims to improve patient outcomes and ultimately cure cancer through combination immunotherapy. Their expertise encompasses oncolytic virus design, gene therapy vector discovery, and the development of experimental cancer therapeutics, positioning them at the forefront of biotechnological advancements in the fight against cancer.

Medivation, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at treating serious diseases with limited treatment options. The company specializes in small molecule drugs and is notably collaborating with Astellas Pharma to develop MDV3100 for various stages of advanced prostate cancer, having completed a Phase III trial for the drug. Medivation operates three subsidiaries: Medivation Prostate Therapeutics, which focuses on the MDV300 series technology for advanced prostate cancer; Medivation Neurology, which was engaged in developing dimebon for Alzheimer’s disease and Huntington's disease; and Medivation Technologies, which oversees earlier-stage technologies. Through its efforts, Medivation strives to provide effective treatment alternatives for critically ill patients and their families.

Bamboo Therapeutics is a biotechnology company focused on advancing gene therapies for the treatment of monogenic disorders, particularly those affecting the central nervous system and neuromuscular conditions. Founded to translate the pioneering work of Dr. Richard Jude Samulski, a leading figure in gene therapy, the company aims to move innovative treatments from the laboratory into human clinical trials, ultimately seeking drug approval. Dr. Samulski, recognized for his groundbreaking use of adeno-associated virus (AAV) as a vehicle for gene replacement, has significantly contributed to the field through the development of over twenty patents related to AAV therapeutic applications. Bamboo Therapeutics leverages his expertise in vector optimization and AAV re-engineering to enhance the safety and efficacy of its gene therapies.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

Hospira specializes in the development, manufacturing, distribution, and marketing of injectable drugs and infusion technologies worldwide. Its portfolio includes specialty injectable pharmaceuticals like Precedex, Retacrit, Nivestim, Inflectra, along with medication management products such as infusion pumps and software systems. Additionally, Hospira offers intravenous solutions, nutritional products, and contract manufacturing services.

Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field.

InnoPharma, LLC, founded in 2005 and located in Piscataway, New Jersey, is a privately held pharmaceutical research and development company. The firm specializes in developing complex generic and innovative specialty pharmaceutical and bio-pharmaceutical products, particularly in injectable and ophthalmic dosage forms. InnoPharma boasts a diverse portfolio of products in various stages of development, utilizing advanced formulations such as suspensions, lyophilized products, emulsions, liposomes, micelles, and lipid complexes.

NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative products utilizing proprietary drug delivery technology. The company is primarily focused on creating once-daily liquid medications aimed at treating attention deficit/hyperactivity disorder (ADHD). By leveraging its unique drug delivery systems, NextWave Pharmaceuticals enables healthcare providers to effectively address various disorders related to the central nervous system, enhancing treatment options for patients.

Excaliard Pharmaceuticals is a biotechnology company focused on developing and commercializing antisense drugs specifically for the local treatment of scarring and other fibrotic diseases. By creating targeted therapeutics, the company aims to address dermatological disorders and provide patients with enhanced treatment options for conditions related to fibrosis. With a commitment to advancing medical care in this area, Excaliard is positioned to make significant contributions to the field of dermatology.

Icagen, Inc. is a biopharmaceutical company based in Durham, North Carolina, specializing in drug discovery with a particular emphasis on neuroscience and rare diseases. Founded in 2003, the company focuses on developing novel orally-administered small molecule drugs that target ion channels, among other therapeutic areas. Icagen provides a range of pre-clinical drug discovery services, including assay development, cell line generation, high-throughput screening, medicinal and computational chemistry, and custom assay services. The company's drug pipeline includes ICA-105665, currently in Phase I trials for epilepsy and neuropathic pain, and Senicapoc, which is undergoing Phase I studies for asthma. Icagen actively collaborates with major pharmaceutical companies, such as Bristol-Myers Squibb, Astellas Pharma, and Pfizer, to advance its research and development initiatives.

King Pharmaceuticals, Inc. is a vertically integrated pharmaceutical company engaged in the research, development, manufacturing, marketing, and sales of branded prescription pharmaceutical products and animal health products. The company's portfolio includes neuroscience products, primarily pain medications, hospital products, and established brands for human use. Additionally, King Pharmaceuticals operates an auto-injector business that specializes in delivering acute care medicines through auto-injector devices. In the animal health sector, the company focuses on medicated feed additives and water-soluble therapeutics mainly for poultry, cattle, and swine. King's operations are organized into four segments: a specialty-driven branded prescription pharmaceuticals business, a global animal health business, the Meridian auto-injector division, and revenues from royalties and other sources.

FoldRx Pharmaceuticals, Inc. is engaged in the discovery and development of disease-modifying drug therapies targeting diseases caused by protein misfolding and amyloidosis. Based in Cambridge, Massachusetts, the company focuses on addressing conditions related to the accumulation of misfolded proteins, which can result from genetic mutations or defects in cellular quality control mechanisms. Its pipeline includes advanced clinical programs aimed at treating transthyretin-associated amyloidoses, specifically those affecting the nervous and cardiovascular systems. Additionally, FoldRx is exploring therapeutic options for Parkinson's disease and cystic fibrosis. Founded in 2003, the company aims to provide healthcare professionals with effective treatments for these complex conditions.

Wyeth Biopharma

Wyeth Nutritionals is a high-quality, high-growth infant nutrition business with strong brands, value-creating and accretives.

Catapult Genetics Pty., Ltd. is a developer and provider of DNA testing services focused on the livestock and aquaculture industries. The company specializes in commercializing DNA tests and gene markers designed to enhance meat production and quality, thus improving efficiency for food producers, processors, and retailers. Its product offerings include GeneSTAR tests for feed efficiency, marbling, and tenderness, as well as SireTRACE for parentage identification. Additionally, Catapult Genetics provides SureTRAK for traceability of meat products, GH Exon 5 for evaluating wagyu cattle, and SCD for selecting cattle based on genotype. The company serves a diverse clientele, including stud and commercial breeders, pastoral companies, and biotechnology firms, through distribution partners in regions such as the United Kingdom, North and South America, Europe, and South Africa. Founded in 1998 and based in Albion, Australia, Catapult Genetics operates in Australia and New Zealand and was previously known as Genetic Solutions Pty Ltd.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Encysive Pharmaceuticals, Inc. is a biopharmaceutical company based in Houston, Texas, focused on discovering, developing, and commercializing synthetic and small molecule compounds to meet global medical needs. Established in 1989 and previously known as Texas Biotechnology Corporation, Encysive specializes in addressing diseases related to the vascular endothelium, inflammatory processes, and various vascular conditions. Its product portfolio includes Argatroban, which is used for the treatment of heparin-induced thrombocytopenia, and Thelin (sitaxsentan sodium), an endothelin receptor antagonist aimed at treating pulmonary arterial hypertension, congestive heart failure, and essential hypertension. The company's research pipeline features several clinical development compounds, including TBC3711, TBC4746, ENC8003, and bimosiamose, targeting conditions such as cardiovascular diseases and inflammatory disorders. Encysive Pharmaceuticals has established collaborations and licensing agreements with major pharmaceutical companies, enhancing its research capabilities and market reach. As of 2008, Encysive operates as a subsidiary of Pfizer Inc.

Covx is a biotechnology company. It engages in the discovery and development of long-acting biological therapies called CovX-Bodies. Its products pipeline focuses on targets that inhibit tumor angiogenesis and modulate metabolic disorders. Their products pipeline includes CVX-045, a thrombospondin-1 mimetic CovX-Body; TSP-1, a negative regulator of angiogenesis that acts as a therapeutic target in oncology; CVX-060, a selective angiopoietin-2 antagonist COVX-BODY; and CVX-096, a long-acting GLP-1 mimetic COVX-BODY. Covx was founded by Carlos Barbas in 2002 and is headquartered in San Diego, California.

Founded in 1997 and headquartered in Wellesley, Massachusetts, Coley Pharmaceutical Group is a biopharmaceutical company focused on developing therapeutics that harness the human immune system to combat cancers, asthma and allergy, autoimmune disorders, and enhance vaccine effectiveness. The company's platform specializes in vaccine adjuvant technology and immunomodulatory drug candidates.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

PowderMed developed vaccines for the treatment of chronic infectious diseases and cancer. The company used DNA coated gold particles delivered by a needle-free injection device to stimulate a powerful and specific T cell immune response.

Rinat Neuroscience, established in 2001 as a spin-out from Genentech, specializes in the development of protein-based therapeutics targeting diseases and disorders of the nervous system. The company leverages over 15 years of research and development support from Genentech to advance its innovative pipeline. Rinat focuses on creating antibody drugs for various conditions, including pain, Alzheimer's disease, obesity, diabetes, and neuropathies. In addition to these therapeutic areas, Rinat is engaged in developing novel disease-modifying therapies aimed at modulating neuronal function and preventing or reversing damage to specific populations of neurons affected by these diseases.

Antibody discovery and optimization company developing a rational approach to antibody engineering.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Angiosyn, Inc. is a biopharmaceutical company focused on developing innovative proprietary biologics aimed at controlling angiogenesis. The company's primary therapeutic focus is on ophthalmic diseases, specifically targeting conditions such as macular degeneration and diabetic retinopathy. These conditions, driven by abnormal blood vessel growth, can result in significant vision impairment and potential blindness. Angiosyn’s research and development efforts are directed towards creating effective treatments that address the underlying mechanisms of these diseases, ultimately improving patient outcomes in ocular health.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Pharmacia Corporation, established in 1901, is a global pharmaceutical company headquartered in Kalamazoo, Michigan, with operations across the United States, Europe, Asia, and Puerto Rico. It specializes in developing, manufacturing, and marketing prescription pharmaceutical products, focusing on primary care, hospital care, cancer care, ophthalmology, and endocrine care. Pharmacia's portfolio spans various therapeutic areas such as cardiology, endocrinology, neuroscience, rheumatology, urology, oncology, and others. It serves a diverse range of customers including pharmacies, hospitals, wholesalers, governments, and physicians. As of April 16, 2003, Pharmacia operates as a subsidiary of Pfizer Inc.

Warner-Lambert was a prominent U.S.-based pharmaceutical company founded in 1856 by William Warner in Philadelphia. Initially, Warner focused on producing sweet-tasting tablets to mask the unpleasant flavors of medicines. In 1955, Warner merged with Lambert Pharmacal Company, known for its Listerine product, to form Warner-Lambert Pharmaceutical Company. The company expanded significantly through acquisitions, including American Chicle Company in 1962, recognized for its Chiclets gum, and Parke-Davis in 1970, which was once the world's largest drug manufacturer. In 1993, Warner-Lambert also acquired Wilkinson Sword. This growth trajectory culminated in its acquisition by Pfizer in 2000, marking the end of its independent operations.

It is a Romanian pharmaceutical company